Biosimilars Canada has welcomed the government of Quebec’s decision to implement and release details of the Canadian province’s biosimilar switching policy, that aims to “increase the use of biosimilar medicines under the Public Prescription Drug Insurance Plan and generate significant savings for the province.”
The Canadian association representing the biosimilar industry noted that Quebec’s biosimilar policy is expected to generate annual savings of CAD100m...






